Clinical Trials Browser

Phase 2 × Sezary Syndrome × Bortezomib × Clear all

NCT00182637 2020-08-03

Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

Phase 2 Completed

5 enrolled 4 charts

DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous